Review



human c5ar2 rabbit polyclonal antibody cat  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Merck & Co human c5ar2 rabbit polyclonal antibody cat
    a High C5a expression in human PDAC cell cytoplasm ( n = 90). Original magnification: ×200. b Low C5a expression in human PDAC cell cytoplasm ( n = 40). Original magnification: ×200. c High C5aR1 expression in human PDAC cell cytoplasm ( n = 62). Original magnification: ×200. d Low C5aR1 expression in human PDAC cell cytoplasm ( n = 68). Original magnification: ×200. e High <t>C5aR2</t> expression in human PDAC cell cytoplasm ( n = 102). Original magnification: ×200. f Low C5aR2 expression in human PDAC cell cytoplasm ( n = 28). Original magnification: ×200. g – i Images of the immunofluorescence (IF) staining of DAPI (blue), C5a (green), and C5aR1 (red) expression in the human PDAC cytoplasm. C5a and C5aR1 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. j – l Images of IF staining of DAPI (blue), C5a (green), and C5aR2 (red) expression in the human PDAC cytoplasm. C5a and C5aR2 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. m Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 axis (C5a-C5aR1 c-axis). The high C5a-C5aR1 c-axis group presented significantly shorter OS ( p = 0.0078, log-rank test) than low C5a-C5aR1 c-axis group. n Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR2 axis (defined: C5a-C5aR2 c-axis). The Low C5a-C5aR2 c-axis group presented significantly shorter OS ( p = 0.049, log-rank test) than the High C5a-C5aR2 c-axis group. o Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 c-axis and C5a-C5aR2 c-axis combination. The high C5a-C5aR1 c-axis and low C5aR2 c-axis group presented significantly shorter OS than other groups ( p = 0.0001, log-rank test).
    Human C5ar2 Rabbit Polyclonal Antibody Cat, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+c5ar2+rabbit+polyclonal+antibody+cat/antibody+c5ar2+cat+human+polyclonal+rabbit/pmc12690149-39-75-84
    Average 86 stars, based on 1 article reviews
    human c5ar2 rabbit polyclonal antibody cat - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma"

    Article Title: Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma

    Journal: British Journal of Cancer

    doi: 10.1038/s41416-025-03185-0

    a High C5a expression in human PDAC cell cytoplasm ( n = 90). Original magnification: ×200. b Low C5a expression in human PDAC cell cytoplasm ( n = 40). Original magnification: ×200. c High C5aR1 expression in human PDAC cell cytoplasm ( n = 62). Original magnification: ×200. d Low C5aR1 expression in human PDAC cell cytoplasm ( n = 68). Original magnification: ×200. e High C5aR2 expression in human PDAC cell cytoplasm ( n = 102). Original magnification: ×200. f Low C5aR2 expression in human PDAC cell cytoplasm ( n = 28). Original magnification: ×200. g – i Images of the immunofluorescence (IF) staining of DAPI (blue), C5a (green), and C5aR1 (red) expression in the human PDAC cytoplasm. C5a and C5aR1 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. j – l Images of IF staining of DAPI (blue), C5a (green), and C5aR2 (red) expression in the human PDAC cytoplasm. C5a and C5aR2 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. m Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 axis (C5a-C5aR1 c-axis). The high C5a-C5aR1 c-axis group presented significantly shorter OS ( p = 0.0078, log-rank test) than low C5a-C5aR1 c-axis group. n Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR2 axis (defined: C5a-C5aR2 c-axis). The Low C5a-C5aR2 c-axis group presented significantly shorter OS ( p = 0.049, log-rank test) than the High C5a-C5aR2 c-axis group. o Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 c-axis and C5a-C5aR2 c-axis combination. The high C5a-C5aR1 c-axis and low C5aR2 c-axis group presented significantly shorter OS than other groups ( p = 0.0001, log-rank test).
    Figure Legend Snippet: a High C5a expression in human PDAC cell cytoplasm ( n = 90). Original magnification: ×200. b Low C5a expression in human PDAC cell cytoplasm ( n = 40). Original magnification: ×200. c High C5aR1 expression in human PDAC cell cytoplasm ( n = 62). Original magnification: ×200. d Low C5aR1 expression in human PDAC cell cytoplasm ( n = 68). Original magnification: ×200. e High C5aR2 expression in human PDAC cell cytoplasm ( n = 102). Original magnification: ×200. f Low C5aR2 expression in human PDAC cell cytoplasm ( n = 28). Original magnification: ×200. g – i Images of the immunofluorescence (IF) staining of DAPI (blue), C5a (green), and C5aR1 (red) expression in the human PDAC cytoplasm. C5a and C5aR1 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. j – l Images of IF staining of DAPI (blue), C5a (green), and C5aR2 (red) expression in the human PDAC cytoplasm. C5a and C5aR2 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. m Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 axis (C5a-C5aR1 c-axis). The high C5a-C5aR1 c-axis group presented significantly shorter OS ( p = 0.0078, log-rank test) than low C5a-C5aR1 c-axis group. n Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR2 axis (defined: C5a-C5aR2 c-axis). The Low C5a-C5aR2 c-axis group presented significantly shorter OS ( p = 0.049, log-rank test) than the High C5a-C5aR2 c-axis group. o Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 c-axis and C5a-C5aR2 c-axis combination. The high C5a-C5aR1 c-axis and low C5aR2 c-axis group presented significantly shorter OS than other groups ( p = 0.0001, log-rank test).

    Techniques Used: Expressing, Immunofluorescence, Staining

    a Western blot analysis of C5a and C5aR1, C5aR2 expression in various human pancreatic cell lines, including cell lines of primary PDAC (BxPC-3, MIA PaCa-2, PANC-1, Capan-2), metastatic PDAC ascites (AsPC-1), lymph node metastasis (Hs766T), and PDAC liver metastases (CFPAC-1, Capan-1). b Western blot analysis of the C5aR1 knockdown with C5aR1siRNA transfection in MIA PaCa-2, BxPC-3 cells. The expression of C5aR1 in C5aR1siRNA1, 2-transfected cells was decreased by normalisation with β-actin compared to the control siRNA cells. c Proliferation assays using C5aR1siRNAs-transfected cells. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had undergone C5aR1 knockdown with C5aR1siRNA1, 2 transfection, showed significant reduction after 48 h in both cells when compared to the control siRNA group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). d The efficacy of C5aR1 selective inhibitor (CCX168) in proliferation assays. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). e Western blot analysis with C5aR1siRNA-transfected cells (MIA PaCa-2, BxPC-3) showed decreasing expression of p-PI3K, p-AKT, and p-mTOR by normalisation with β-actin compared to the control cells, whereas the expression of t-PI3K, t-AKT, and t-mTOR showed no difference compared to the control cells. f The analyses of proliferation using Gemcitabine (Gem) and CCX168. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test). In addition, proliferation in MIA PaCa-2 cells was significantly inhibited after 48 h in the Gem and CCX168 combined group compared to the Gem or CCX168 group. g , h Apoptosis assay utilising annexin V and PI using MIA PaCa-2 cells. The number of early apoptotic cells that were positive for Annexin V, but negative for PI, was significantly increased in the group treated with Gem in combination with C5aR1siRNA transfection or CCX168 group compared to Gem group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test).
    Figure Legend Snippet: a Western blot analysis of C5a and C5aR1, C5aR2 expression in various human pancreatic cell lines, including cell lines of primary PDAC (BxPC-3, MIA PaCa-2, PANC-1, Capan-2), metastatic PDAC ascites (AsPC-1), lymph node metastasis (Hs766T), and PDAC liver metastases (CFPAC-1, Capan-1). b Western blot analysis of the C5aR1 knockdown with C5aR1siRNA transfection in MIA PaCa-2, BxPC-3 cells. The expression of C5aR1 in C5aR1siRNA1, 2-transfected cells was decreased by normalisation with β-actin compared to the control siRNA cells. c Proliferation assays using C5aR1siRNAs-transfected cells. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had undergone C5aR1 knockdown with C5aR1siRNA1, 2 transfection, showed significant reduction after 48 h in both cells when compared to the control siRNA group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). d The efficacy of C5aR1 selective inhibitor (CCX168) in proliferation assays. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). e Western blot analysis with C5aR1siRNA-transfected cells (MIA PaCa-2, BxPC-3) showed decreasing expression of p-PI3K, p-AKT, and p-mTOR by normalisation with β-actin compared to the control cells, whereas the expression of t-PI3K, t-AKT, and t-mTOR showed no difference compared to the control cells. f The analyses of proliferation using Gemcitabine (Gem) and CCX168. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test). In addition, proliferation in MIA PaCa-2 cells was significantly inhibited after 48 h in the Gem and CCX168 combined group compared to the Gem or CCX168 group. g , h Apoptosis assay utilising annexin V and PI using MIA PaCa-2 cells. The number of early apoptotic cells that were positive for Annexin V, but negative for PI, was significantly increased in the group treated with Gem in combination with C5aR1siRNA transfection or CCX168 group compared to Gem group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test).

    Techniques Used: Western Blot, Expressing, Knockdown, Transfection, Control, MANN-WHITNEY, Apoptosis Assay

    Related Articles

    Control:

    Article Title: Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma.
    Article Snippet: The detailed information of C5a, C5/ C5b, C5aR1, and C5aR2 antibodies was indicated as follows; Human C5a mouse monoclonal antibody (D2): cat. no. MA5-43875, Company: Thermo Fisher Scientific Japan, Degree of dilution for IHC and IF: 1:100; Human C5/C5b monoclonal antibody: cat. no. HA255621, Company: ABclonal, Degree of dilution for IHC: 1:100; DMSO Gem CCX168 Gem+CCX168 ** ** ** * MIA PaCa-2 BxPC-3 Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 .. Β-actin Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 2.0 1.5 1.0 0.5 0.0 Time after siRNA transfection (hours) * ** ** MIA PaCa-2 2.0 1.5 1.0 0.5 0.0 * ** ** BxPC-3 1.0 0.5 1.5 0.0 2.0 2.5 * ** ** DMSO CCX168 1.0 0.5 1.5 0.0 2.0 2.5 * ** ** b c d MIA PaCa-2 BxPC-3 a Time after siRNA transfection (hours) Time after cell seeding (hours) 0 24 48 72 96 0 24 48 72 96 0 24 48 72 96 0 24 48 72 96 Time after cell seeding (hours) ControlsiRNA C5aR1siRNA1 C5aR1siRNA2 ControlsiRNA C5aR1siRNA1 C5aR1siRNA2 DMSO CCX168 A bs or ba nc e at 4 50 n m A bs or ba nc e at 4 50 n m A bs or ba nc e at 4 50 n m C5aR1 C5aR2 Β-actin C5a A bs or ba nc e at 4 50 n m 2.0 1.5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 MIA PaCa-2 BxPC-3 A bs or ba nc e at 4 50 n m DMSO Gem CCX168 Gem+CCX168 f Time after cell seeding (hours) 0 24 48 72 960 24 48 72 96 Time after cell seeding (hours) A bs or ba nc e at 4 50 n m ** ** ** ** *; p < 0.05, **; p < 0.01 P I Annexin V Gem Gem+CCX168 C5aR1siRNA1 Gem+C5aR1siRNA1 Control Early apoptotic cells MIA PaCa-2 g 0 20 15 10 5E ar ly a po pt ot ic c el ls ( % ) * ** * *h *; p < 0.05, **; p < 0.01 MIA PaCa-2 BxPC-3 Β-actin t-PI3K p-PI3K t-AKT p-AKT t-mTOR p-mTOR e Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 *; p < 0.05, **; p < 0.01 *; p < 0.05, **; p < 0.01 HPD E BxP C-3 MIA Pa Ca2 PAN C-1 Cap an2 Cap an1 AsP C-1 Hs7 66T CEP AC- 1 Co nt ro l C5 aR 1s iR NA 1 Ge m Ge m +C CX 16 8 Ge m +C 5a R1 siR NA 1 105 105 104 104 103 103 –103 –103 010 5 104 103 –103 0 0 105104103–103 0 105104103–103 0 105104103–103 0 105104103–103 0 105 104 103 –103 0 105 104 103 –103 0 105 104 103 –103 0 British Journal of Cancer Human C5aR1 rabbit polyclonal antibody: cat. no. A1900, Company: ABclonal Hubei China, Cross-reactivity: mouse, rat, Degree of dilution for IHC and IF: 1:150; Human C5aR2 rabbit polyclonal antibody: cat. no. HPA016629, Company: Merck Ltd./Sigma-Aldrich Japan G.K., Degree of dilution for IHC and IF: 1:75. ..

    Transfection:

    Article Title: Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma.
    Article Snippet: The detailed information of C5a, C5/ C5b, C5aR1, and C5aR2 antibodies was indicated as follows; Human C5a mouse monoclonal antibody (D2): cat. no. MA5-43875, Company: Thermo Fisher Scientific Japan, Degree of dilution for IHC and IF: 1:100; Human C5/C5b monoclonal antibody: cat. no. HA255621, Company: ABclonal, Degree of dilution for IHC: 1:100; DMSO Gem CCX168 Gem+CCX168 ** ** ** * MIA PaCa-2 BxPC-3 Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 .. Β-actin Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 2.0 1.5 1.0 0.5 0.0 Time after siRNA transfection (hours) * ** ** MIA PaCa-2 2.0 1.5 1.0 0.5 0.0 * ** ** BxPC-3 1.0 0.5 1.5 0.0 2.0 2.5 * ** ** DMSO CCX168 1.0 0.5 1.5 0.0 2.0 2.5 * ** ** b c d MIA PaCa-2 BxPC-3 a Time after siRNA transfection (hours) Time after cell seeding (hours) 0 24 48 72 96 0 24 48 72 96 0 24 48 72 96 0 24 48 72 96 Time after cell seeding (hours) ControlsiRNA C5aR1siRNA1 C5aR1siRNA2 ControlsiRNA C5aR1siRNA1 C5aR1siRNA2 DMSO CCX168 A bs or ba nc e at 4 50 n m A bs or ba nc e at 4 50 n m A bs or ba nc e at 4 50 n m C5aR1 C5aR2 Β-actin C5a A bs or ba nc e at 4 50 n m 2.0 1.5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 MIA PaCa-2 BxPC-3 A bs or ba nc e at 4 50 n m DMSO Gem CCX168 Gem+CCX168 f Time after cell seeding (hours) 0 24 48 72 960 24 48 72 96 Time after cell seeding (hours) A bs or ba nc e at 4 50 n m ** ** ** ** *; p < 0.05, **; p < 0.01 P I Annexin V Gem Gem+CCX168 C5aR1siRNA1 Gem+C5aR1siRNA1 Control Early apoptotic cells MIA PaCa-2 g 0 20 15 10 5E ar ly a po pt ot ic c el ls ( % ) * ** * *h *; p < 0.05, **; p < 0.01 MIA PaCa-2 BxPC-3 Β-actin t-PI3K p-PI3K t-AKT p-AKT t-mTOR p-mTOR e Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 *; p < 0.05, **; p < 0.01 *; p < 0.05, **; p < 0.01 HPD E BxP C-3 MIA Pa Ca2 PAN C-1 Cap an2 Cap an1 AsP C-1 Hs7 66T CEP AC- 1 Co nt ro l C5 aR 1s iR NA 1 Ge m Ge m +C CX 16 8 Ge m +C 5a R1 siR NA 1 105 105 104 104 103 103 –103 –103 010 5 104 103 –103 0 0 105104103–103 0 105104103–103 0 105104103–103 0 105104103–103 0 105 104 103 –103 0 105 104 103 –103 0 105 104 103 –103 0 British Journal of Cancer Human C5aR1 rabbit polyclonal antibody: cat. no. A1900, Company: ABclonal Hubei China, Cross-reactivity: mouse, rat, Degree of dilution for IHC and IF: 1:150; Human C5aR2 rabbit polyclonal antibody: cat. no. HPA016629, Company: Merck Ltd./Sigma-Aldrich Japan G.K., Degree of dilution for IHC and IF: 1:75. ..

    Immunohistochemistry:

    Article Title: Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma.
    Article Snippet: The detailed information of C5a, C5/ C5b, C5aR1, and C5aR2 antibodies was indicated as follows; Human C5a mouse monoclonal antibody (D2): cat. no. MA5-43875, Company: Thermo Fisher Scientific Japan, Degree of dilution for IHC and IF: 1:100; Human C5/C5b monoclonal antibody: cat. no. HA255621, Company: ABclonal, Degree of dilution for IHC: 1:100; DMSO Gem CCX168 Gem+CCX168 ** ** ** * MIA PaCa-2 BxPC-3 Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 .. Β-actin Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 2.0 1.5 1.0 0.5 0.0 Time after siRNA transfection (hours) * ** ** MIA PaCa-2 2.0 1.5 1.0 0.5 0.0 * ** ** BxPC-3 1.0 0.5 1.5 0.0 2.0 2.5 * ** ** DMSO CCX168 1.0 0.5 1.5 0.0 2.0 2.5 * ** ** b c d MIA PaCa-2 BxPC-3 a Time after siRNA transfection (hours) Time after cell seeding (hours) 0 24 48 72 96 0 24 48 72 96 0 24 48 72 96 0 24 48 72 96 Time after cell seeding (hours) ControlsiRNA C5aR1siRNA1 C5aR1siRNA2 ControlsiRNA C5aR1siRNA1 C5aR1siRNA2 DMSO CCX168 A bs or ba nc e at 4 50 n m A bs or ba nc e at 4 50 n m A bs or ba nc e at 4 50 n m C5aR1 C5aR2 Β-actin C5a A bs or ba nc e at 4 50 n m 2.0 1.5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 MIA PaCa-2 BxPC-3 A bs or ba nc e at 4 50 n m DMSO Gem CCX168 Gem+CCX168 f Time after cell seeding (hours) 0 24 48 72 960 24 48 72 96 Time after cell seeding (hours) A bs or ba nc e at 4 50 n m ** ** ** ** *; p < 0.05, **; p < 0.01 P I Annexin V Gem Gem+CCX168 C5aR1siRNA1 Gem+C5aR1siRNA1 Control Early apoptotic cells MIA PaCa-2 g 0 20 15 10 5E ar ly a po pt ot ic c el ls ( % ) * ** * *h *; p < 0.05, **; p < 0.01 MIA PaCa-2 BxPC-3 Β-actin t-PI3K p-PI3K t-AKT p-AKT t-mTOR p-mTOR e Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 Control siRNA C5aR1 siRNA1 C5aR1 siRNA2 *; p < 0.05, **; p < 0.01 *; p < 0.05, **; p < 0.01 HPD E BxP C-3 MIA Pa Ca2 PAN C-1 Cap an2 Cap an1 AsP C-1 Hs7 66T CEP AC- 1 Co nt ro l C5 aR 1s iR NA 1 Ge m Ge m +C CX 16 8 Ge m +C 5a R1 siR NA 1 105 105 104 104 103 103 –103 –103 010 5 104 103 –103 0 0 105104103–103 0 105104103–103 0 105104103–103 0 105104103–103 0 105 104 103 –103 0 105 104 103 –103 0 105 104 103 –103 0 British Journal of Cancer Human C5aR1 rabbit polyclonal antibody: cat. no. A1900, Company: ABclonal Hubei China, Cross-reactivity: mouse, rat, Degree of dilution for IHC and IF: 1:150; Human C5aR2 rabbit polyclonal antibody: cat. no. HPA016629, Company: Merck Ltd./Sigma-Aldrich Japan G.K., Degree of dilution for IHC and IF: 1:75. ..

    Article Title: Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma
    Article Snippet: .. The detailed information of C5a, C5/C5b, C5aR1, and C5aR2 antibodies was indicated as follows; Human C5a mouse monoclonal antibody (D2): cat. no. MA5-43875, Company: Thermo Fisher Scientific Japan, Degree of dilution for IHC and IF: 1:100; Human C5/C5b monoclonal antibody: cat. no. HA255621 , Company: ABclonal, Degree of dilution for IHC: 1:100; Human C5aR1 rabbit polyclonal antibody: cat. no. A1900, Company: ABclonal Hubei China, Cross-reactivity: mouse, rat, Degree of dilution for IHC and IF: 1:150; Human C5aR2 rabbit polyclonal antibody: cat. no. HPA016629, Company: Merck Ltd./Sigma-Aldrich Japan G.K., Degree of dilution for IHC and IF: 1:75. ..



    Similar Products

    human c5ar2 rabbit polyclonal antibody cat  (Merck & Co)
    86
    Merck & Co human c5ar2 rabbit polyclonal antibody cat
    a High C5a expression in human PDAC cell cytoplasm ( n = 90). Original magnification: ×200. b Low C5a expression in human PDAC cell cytoplasm ( n = 40). Original magnification: ×200. c High C5aR1 expression in human PDAC cell cytoplasm ( n = 62). Original magnification: ×200. d Low C5aR1 expression in human PDAC cell cytoplasm ( n = 68). Original magnification: ×200. e High <t>C5aR2</t> expression in human PDAC cell cytoplasm ( n = 102). Original magnification: ×200. f Low C5aR2 expression in human PDAC cell cytoplasm ( n = 28). Original magnification: ×200. g – i Images of the immunofluorescence (IF) staining of DAPI (blue), C5a (green), and C5aR1 (red) expression in the human PDAC cytoplasm. C5a and C5aR1 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. j – l Images of IF staining of DAPI (blue), C5a (green), and C5aR2 (red) expression in the human PDAC cytoplasm. C5a and C5aR2 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. m Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 axis (C5a-C5aR1 c-axis). The high C5a-C5aR1 c-axis group presented significantly shorter OS ( p = 0.0078, log-rank test) than low C5a-C5aR1 c-axis group. n Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR2 axis (defined: C5a-C5aR2 c-axis). The Low C5a-C5aR2 c-axis group presented significantly shorter OS ( p = 0.049, log-rank test) than the High C5a-C5aR2 c-axis group. o Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 c-axis and C5a-C5aR2 c-axis combination. The high C5a-C5aR1 c-axis and low C5aR2 c-axis group presented significantly shorter OS than other groups ( p = 0.0001, log-rank test).
    Human C5ar2 Rabbit Polyclonal Antibody Cat, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+c5ar2+rabbit+polyclonal+antibody+cat/antibody+c5ar2+cat+human+polyclonal+rabbit/pmc12690149-39-75-84
    Average 86 stars, based on 1 article reviews
    human c5ar2 rabbit polyclonal antibody cat - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    a High C5a expression in human PDAC cell cytoplasm ( n = 90). Original magnification: ×200. b Low C5a expression in human PDAC cell cytoplasm ( n = 40). Original magnification: ×200. c High C5aR1 expression in human PDAC cell cytoplasm ( n = 62). Original magnification: ×200. d Low C5aR1 expression in human PDAC cell cytoplasm ( n = 68). Original magnification: ×200. e High C5aR2 expression in human PDAC cell cytoplasm ( n = 102). Original magnification: ×200. f Low C5aR2 expression in human PDAC cell cytoplasm ( n = 28). Original magnification: ×200. g – i Images of the immunofluorescence (IF) staining of DAPI (blue), C5a (green), and C5aR1 (red) expression in the human PDAC cytoplasm. C5a and C5aR1 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. j – l Images of IF staining of DAPI (blue), C5a (green), and C5aR2 (red) expression in the human PDAC cytoplasm. C5a and C5aR2 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. m Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 axis (C5a-C5aR1 c-axis). The high C5a-C5aR1 c-axis group presented significantly shorter OS ( p = 0.0078, log-rank test) than low C5a-C5aR1 c-axis group. n Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR2 axis (defined: C5a-C5aR2 c-axis). The Low C5a-C5aR2 c-axis group presented significantly shorter OS ( p = 0.049, log-rank test) than the High C5a-C5aR2 c-axis group. o Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 c-axis and C5a-C5aR2 c-axis combination. The high C5a-C5aR1 c-axis and low C5aR2 c-axis group presented significantly shorter OS than other groups ( p = 0.0001, log-rank test).

    Journal: British Journal of Cancer

    Article Title: Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma

    doi: 10.1038/s41416-025-03185-0

    Figure Lengend Snippet: a High C5a expression in human PDAC cell cytoplasm ( n = 90). Original magnification: ×200. b Low C5a expression in human PDAC cell cytoplasm ( n = 40). Original magnification: ×200. c High C5aR1 expression in human PDAC cell cytoplasm ( n = 62). Original magnification: ×200. d Low C5aR1 expression in human PDAC cell cytoplasm ( n = 68). Original magnification: ×200. e High C5aR2 expression in human PDAC cell cytoplasm ( n = 102). Original magnification: ×200. f Low C5aR2 expression in human PDAC cell cytoplasm ( n = 28). Original magnification: ×200. g – i Images of the immunofluorescence (IF) staining of DAPI (blue), C5a (green), and C5aR1 (red) expression in the human PDAC cytoplasm. C5a and C5aR1 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. j – l Images of IF staining of DAPI (blue), C5a (green), and C5aR2 (red) expression in the human PDAC cytoplasm. C5a and C5aR2 are expressed in the PDAC cell cytoplasm, and margin sites were observed (arrowheads). Original magnification: ×200. m Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 axis (C5a-C5aR1 c-axis). The high C5a-C5aR1 c-axis group presented significantly shorter OS ( p = 0.0078, log-rank test) than low C5a-C5aR1 c-axis group. n Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR2 axis (defined: C5a-C5aR2 c-axis). The Low C5a-C5aR2 c-axis group presented significantly shorter OS ( p = 0.049, log-rank test) than the High C5a-C5aR2 c-axis group. o Kaplan–Meier analyses for OS of PDAC patients based on PDAC cell cytoplasmic C5a-C5aR1 c-axis and C5a-C5aR2 c-axis combination. The high C5a-C5aR1 c-axis and low C5aR2 c-axis group presented significantly shorter OS than other groups ( p = 0.0001, log-rank test).

    Article Snippet: The detailed information of C5a, C5/C5b, C5aR1, and C5aR2 antibodies was indicated as follows; Human C5a mouse monoclonal antibody (D2): cat. no. MA5-43875, Company: Thermo Fisher Scientific Japan, Degree of dilution for IHC and IF: 1:100; Human C5/C5b monoclonal antibody: cat. no. HA255621 , Company: ABclonal, Degree of dilution for IHC: 1:100; Human C5aR1 rabbit polyclonal antibody: cat. no. A1900, Company: ABclonal Hubei China, Cross-reactivity: mouse, rat, Degree of dilution for IHC and IF: 1:150; Human C5aR2 rabbit polyclonal antibody: cat. no. HPA016629, Company: Merck Ltd./Sigma-Aldrich Japan G.K., Degree of dilution for IHC and IF: 1:75.

    Techniques: Expressing, Immunofluorescence, Staining

    a Western blot analysis of C5a and C5aR1, C5aR2 expression in various human pancreatic cell lines, including cell lines of primary PDAC (BxPC-3, MIA PaCa-2, PANC-1, Capan-2), metastatic PDAC ascites (AsPC-1), lymph node metastasis (Hs766T), and PDAC liver metastases (CFPAC-1, Capan-1). b Western blot analysis of the C5aR1 knockdown with C5aR1siRNA transfection in MIA PaCa-2, BxPC-3 cells. The expression of C5aR1 in C5aR1siRNA1, 2-transfected cells was decreased by normalisation with β-actin compared to the control siRNA cells. c Proliferation assays using C5aR1siRNAs-transfected cells. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had undergone C5aR1 knockdown with C5aR1siRNA1, 2 transfection, showed significant reduction after 48 h in both cells when compared to the control siRNA group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). d The efficacy of C5aR1 selective inhibitor (CCX168) in proliferation assays. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). e Western blot analysis with C5aR1siRNA-transfected cells (MIA PaCa-2, BxPC-3) showed decreasing expression of p-PI3K, p-AKT, and p-mTOR by normalisation with β-actin compared to the control cells, whereas the expression of t-PI3K, t-AKT, and t-mTOR showed no difference compared to the control cells. f The analyses of proliferation using Gemcitabine (Gem) and CCX168. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test). In addition, proliferation in MIA PaCa-2 cells was significantly inhibited after 48 h in the Gem and CCX168 combined group compared to the Gem or CCX168 group. g , h Apoptosis assay utilising annexin V and PI using MIA PaCa-2 cells. The number of early apoptotic cells that were positive for Annexin V, but negative for PI, was significantly increased in the group treated with Gem in combination with C5aR1siRNA transfection or CCX168 group compared to Gem group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test).

    Journal: British Journal of Cancer

    Article Title: Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma

    doi: 10.1038/s41416-025-03185-0

    Figure Lengend Snippet: a Western blot analysis of C5a and C5aR1, C5aR2 expression in various human pancreatic cell lines, including cell lines of primary PDAC (BxPC-3, MIA PaCa-2, PANC-1, Capan-2), metastatic PDAC ascites (AsPC-1), lymph node metastasis (Hs766T), and PDAC liver metastases (CFPAC-1, Capan-1). b Western blot analysis of the C5aR1 knockdown with C5aR1siRNA transfection in MIA PaCa-2, BxPC-3 cells. The expression of C5aR1 in C5aR1siRNA1, 2-transfected cells was decreased by normalisation with β-actin compared to the control siRNA cells. c Proliferation assays using C5aR1siRNAs-transfected cells. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had undergone C5aR1 knockdown with C5aR1siRNA1, 2 transfection, showed significant reduction after 48 h in both cells when compared to the control siRNA group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). d The efficacy of C5aR1 selective inhibitor (CCX168) in proliferation assays. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.01, Mann–Whitney–Wilcoxon test). e Western blot analysis with C5aR1siRNA-transfected cells (MIA PaCa-2, BxPC-3) showed decreasing expression of p-PI3K, p-AKT, and p-mTOR by normalisation with β-actin compared to the control cells, whereas the expression of t-PI3K, t-AKT, and t-mTOR showed no difference compared to the control cells. f The analyses of proliferation using Gemcitabine (Gem) and CCX168. The absorbance of MIA PaCa-2 and BxPC-3 cells, which had been seeded with CCX168, showed significant reduction after 48 h in both cells when compared to the control group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test). In addition, proliferation in MIA PaCa-2 cells was significantly inhibited after 48 h in the Gem and CCX168 combined group compared to the Gem or CCX168 group. g , h Apoptosis assay utilising annexin V and PI using MIA PaCa-2 cells. The number of early apoptotic cells that were positive for Annexin V, but negative for PI, was significantly increased in the group treated with Gem in combination with C5aR1siRNA transfection or CCX168 group compared to Gem group (* p < 0.05, ** p < 0.001, Mann–Whitney–Wilcoxon test).

    Article Snippet: The detailed information of C5a, C5/C5b, C5aR1, and C5aR2 antibodies was indicated as follows; Human C5a mouse monoclonal antibody (D2): cat. no. MA5-43875, Company: Thermo Fisher Scientific Japan, Degree of dilution for IHC and IF: 1:100; Human C5/C5b monoclonal antibody: cat. no. HA255621 , Company: ABclonal, Degree of dilution for IHC: 1:100; Human C5aR1 rabbit polyclonal antibody: cat. no. A1900, Company: ABclonal Hubei China, Cross-reactivity: mouse, rat, Degree of dilution for IHC and IF: 1:150; Human C5aR2 rabbit polyclonal antibody: cat. no. HPA016629, Company: Merck Ltd./Sigma-Aldrich Japan G.K., Degree of dilution for IHC and IF: 1:75.

    Techniques: Western Blot, Expressing, Knockdown, Transfection, Control, MANN-WHITNEY, Apoptosis Assay